Drug Profile
Physostigmine - AbbVie
Alternative Names: Nicosim; SynaptonLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Forest Laboratories
- Developer Forest Laboratories; Neurobiological Technologies
- Class Alkaloids; Antidementias; Antidotes; Antiglaucomas; Phenylcarbamates; Small molecules; Smoking cessation therapies
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease; Smoking withdrawal
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Sep 2001 Discontinued-II for Alzheimer's disease in Germany (Transdermal)
- 04 Sep 2001 No-Development-Reported for Alzheimer's disease in Ireland (PO)